Clinical trial

A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

NCT05498428

Study summary

ClinicalTrials.gov

A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

6 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Mapped RxNorm record Amivantamab Normalized identity: amivantamab View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Lazertinib Normalized identity: lazertinib View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Carboplatin Normalized identity: carboplatin View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Pemetrexed Normalized identity: pemetrexed View linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Direct Oral Anticoagulant (DOAC) Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Low Molecular Weight Heparin (LMWH) Find medicine records · Find other trials using this name

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2022-11-11

PhasePHASE2

Conditions

Carcinoma, Non-small-Cell Lungunresolved

Interventions

AmivantamabDRUG · verified · RxNorm: amivantamab

LazertinibDRUG · verified · RxNorm: lazertinib

CarboplatinDRUG · verified · RxNorm: carboplatin

PemetrexedDRUG · verified · RxNorm: pemetrexed

Direct Oral Anticoagulant (DOAC)DRUG

Low Molecular Weight Heparin (LMWH)DRUG

Sponsors & collaborators

Janssen Research & Development, LLClead sponsor

Mapped research locations

MadridSpain4 BarcelonaSpain4 SeoulSouth Korea3 São PauloBrazil3 SeattleWashington, United States2 ClevelandOhio, United States2 MilanItaly2 ValenciaSpain2 ChengduChina2 HangzhouChina2 BostonMassachusetts, United States1 BaltimoreMaryland, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05498428 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.